Celebrating 25 years Est 1999-2024
*Across 3 years $2276.64 only $796.82
Reiterated guidance on data readout from MYTHIC trial evaluating lunresertib and camonsertib in patients with platinum-resistant ovarian and...
Alberta Enterprise Corporation invests US$7.5 million into Amplitude precision medicine fund Canada...
Overall response of 18.2% in heavily pretreated patients across gastrointestinal tumors with target alterations regardless of prior irinotecan...
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the...
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that...
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, announced initial data...
A biotech company is turning heads so far during Wednesday’s premarket hours following the company reporting higher than expected revenue...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.